Size | Price | Stock | Qty |
---|---|---|---|
5mg |
|
||
10mg |
|
||
25mg |
|
||
50mg |
|
||
100mg |
|
||
250mg |
|
||
500mg |
|
||
Other Sizes |
|
Gilteritinib (formerly ASP-2215; ASP2215; Trade name: Xospata) is a potent small-molecule inhibitor of FLT3/AXL approved for treating acute myeloid leukemia (AML). It inhibits FLT3 and AXL with IC50 values of 0.29 nM and 0.73 nM, respectively. At an IC50 approximately 800-fold higher than that needed to inhibit c-KIT (230 nM), gelderitinib potently inhibits FLT3. For leukemias like AML with FLT3-ITD and FLT3-D835 mutations, gelderitinib may be used as a remedy. An IC50 value of 0.29 nM for FLT3 indicates that gelderitinib is approximately 800-fold more potent than c-KIT. Of the 78 tyrosine kinases examined in vitro, it inhibits FLT3, leukocyte tyrosine kinase (LTK), anaplastic lymphoma kinase (ALK), and AXL kinases by over 50% at 1 nM concentration. In order to treat patients with relapsed or refractory acute myeloid leukemia (AML), the US FDA approved gelderitinib in November of 2018.
Targets |
FLT3 (IC50 = 0.29 nM); LTK (IC50 = 0.35 nM); AXL (IC50 = 0.73 nM); EML4-ALK (IC50 = 1.2 nM); c-KIT (IC50 = 230 nM)
|
|
---|---|---|
ln Vitro |
|
|
ln Vivo |
|
|
Enzyme Assay |
TK-ELISA or off-chip mobility shift assays are used to test the kinase inhibitory activity of Gilteritinib against a panel of 78 tested kinases, with ATP concentrations roughly equivalent to each kinase's Km value. Initially, the inhibitory effect of each compound on TK activity is evaluated at two concentrations of Gilteritinib (1 nM and 5 nM). Next, additional research employing a range of Gilteritinib doses is carried out to ascertain IC50 values for c-KIT and kinases whose activity is inhibited by more than half at 1 nM Gilteritinib. FLT3, LTK, AXL, and c-KIT IC50 studies are carried out using TK-ELISA and MSA assays; the HTRF KinEASE-TK assay is used to determine the IC50 value of echinoderm microtubule-associated protein-like 4-ALK (EML4-ALK)[2].
|
|
Cell Assay |
The CellTiter-Glo Luminescent Cell Viability Assay is used to evaluate the impact of gelderitinib on MV4-11 and MOLM-13 cells. Further research is done to investigate the impact of quizartinib and gilteritinib on Ba/F3 cells that express FLT3-ITD, FLT3-D835Y, FLT3-ITD-D835Y, FLT3-ITD-F691 L, or FLT3-ITD-F691I. For five days, DMSO or increasing concentrations of Gilteritinib (0.01, 0.1, 1, 10, and 100 nM) are applied to MV4-11 and MOLM-13 cells. CellTiter-Glo is used to measure the viability of the cells[2].
|
|
Animal Protocol |
Mice: In nude mice transplanted with MV4-11 AML cells, antitumor activity is assessed. Additionally, the pharmacokinetics in xenografted mice are examined. Gilteritinib (10 mg/kg) is given orally to MV4-11 xenografted mice for a period of four days as part of their treatment. Gilteritinib treatment for 28 days causes total tumor regression at doses greater than 6 mg/kg and dose-dependent inhibition of MV4-11 tumor growth[1].
|
|
References |
Molecular Formula |
C29H44N8O3
|
---|---|
Molecular Weight |
552.71
|
Exact Mass |
552.35
|
Elemental Analysis |
C, 63.02; H, 8.02; N, 20.27; O, 8.68
|
CAS # |
1254053-43-4
|
Related CAS # |
Gilteritinib hemifumarate;1254053-84-3;Gilteritinib-d8;2377109-74-3
|
Appearance |
Yellow solid powder
|
SMILES |
CCC1=C(N=C(C(=N1)C(=O)N)NC2=CC(=C(C=C2)N3CCC(CC3)N4CCN(CC4)C)OC)NC5CCOCC5
|
InChi Key |
GYQYAJJFPNQOOW-UHFFFAOYSA-N
|
InChi Code |
InChI=1S/C29H44N8O3/c1-4-23-28(31-20-9-17-40-18-10-20)34-29(26(33-23)27(30)38)32-21-5-6-24(25(19-21)39-3)37-11-7-22(8-12-37)36-15-13-35(2)14-16-36/h5-6,19-20,22H,4,7-18H2,1-3H3,(H2,30,38)(H2,31,32,34)
|
Chemical Name |
6-ethyl-3-[3-methoxy-4-[4-(4-methylpiperazin-1-yl)piperidin-1-yl]anilino]-5-(oxan-4-ylamino)pyrazine-2-carboxamide
|
Synonyms |
ASP-2215; ASP2215; ASP 2215; Gilteritinib; Trade name: Xospata
|
HS Tariff Code |
2934.99.9001
|
Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
Solubility (In Vitro) |
|
|||
---|---|---|---|---|
Solubility (In Vivo) |
Solubility in Formulation 1: 10 mg/mL (18.09 mM) in 50% PEG300 50% Saline (add these co-solvents sequentially from left to right, and one by one), suspension solution; with sonication.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: 5%DMSO+40%PEG300+5%Tween80+50%ddH2O: 0.2mg/ml  (Please use freshly prepared in vivo formulations for optimal results.) |
Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
1 mM | 1.8093 mL | 9.0463 mL | 18.0927 mL | |
5 mM | 0.3619 mL | 1.8093 mL | 3.6185 mL | |
10 mM | 0.1809 mL | 0.9046 mL | 1.8093 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration: mg/mL;
Method for preparing DMSO stock solution: mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation::Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O,mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
NCT04336982 | Active Recruiting |
Drug: Gilteritinib Drug: Azacitidine |
Leukemia, Myeloid, Acute | Celgene | August 5, 2020 | Phase 1 Phase 2 |
NCT03836209 | Active Recruiting |
Drug: Gilteritinib Drug: Midostaurin |
Acute Myeloid Leukemia | PrECOG, LLC. | December 6, 2019 | Phase 2 |
NCT02421939 | Active Recruiting |
Drug: gilteritinib Drug: Azacitidine |
Leukemia, Acute Myeloid (AML) | Astellas Pharma Global Development, Inc. |
October 20, 2015 | Phase 3 |
NCT05791890 | Completed | Drug: Gilteritinib | Acute Myeloid Leukemia | University of Rome Tor Vergata | May 31, 2022 | |
NCT04027309 | Active Recruiting |
Drug: Gilteritinib Drug: Midostaurin |
Myelodysplastic Syndrome With Excess Blasts-2 Acute Myeloid Leukemia |
Stichting Hemato-Oncologie voor Volwassenen Nederland |
December 20, 2019 | Phase 3 |
Gilteritinib inhibits cell growth in AML cells and blocks phosphorylation of FLT3 and its downstream targets.Invest New Drugs.2017 Oct;35(5):556-565. th> |
---|
Antitumor activity of gilteritinib in an MV4–11 xenograft AML mouse model.Invest New Drugs.2017 Oct;35(5):556-565. td> |
Gilteritinib significantly decreases leukemic burden and increases survival in an intra-bone marrow transplantation model of AML.Invest New Drugs.2017 Oct;35(5):556-565. td> |
Computational modeling of gilteritinib binding to wild-type FLT3.Invest New Drugs.2017 Oct;35(5):556-565. th> |
---|
Gilteritinib induces regression of FLT3 mutant-expressing tumors in a mouse xenograft model.Invest New Drugs.2017 Oct;35(5):556-565. td> |
Antitumor Effect of Gilteritinib in Combination with Azacitidine in Mice Xenografted with MV4-11 Cells.Blood. 2016, 128:2830. td> |